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Abstract
Background: Well-designed studies of complications and readmission rates in patients undergoing total hip
arthroplasty (THA) with osteonecrosis are lacking. Our objective was to examine if a diagnosis of osteonecrosis
was associated with complications, mortality and readmission rates after THA.
Methods: We analyzed prospectively collected data from an integrated healthcare system’s Total Joint
Replacement Registry of adults with osteonecrosis vs. osteoarthritis (OA) undergoing unilateral primary THA
during 2001–2012, in an observational cohort study. We examined mortality (90-day), revision (ever), deep
(1 year) and superficial (30-day) surgical site infection (SSI), venous thromboembolism (VTE, 90-day), and
unplanned readmission (90-day). Age, gender, race, body mass index, American Society of Anesthesiologists
class, and diabetes were evaluated as confounders. We used logistic or Cox regression to calculate odds or
hazard ratios (OR, HR) with 95% confidence intervals (CI).
Results: Of the 47,523 primary THA cases, 45,252 (95.2%) had OA, and 2,271 (4.8%) had osteonecrosis. Compared
to the OA, patients with osteonecrosis were younger (median age 55 vs. 67 years), and were less likely to be female
(42.5% vs. 58.3%) or White (59.8% vs. 77.4%). Compared to the OA, the osteonecrosis cohort had higher crude
incidence of 90-day mortality (0.7% vs. 0.3%), SSI (1.2% vs. 0.8%), unplanned readmission (9.6% vs. 5.2%) and
revision (3.1% vs. 2.4%). After multivariable-adjustment, patients with osteonecrosis had a higher odds/hazard
of mortality (OR: 2.48; 95% CI:1.31–4.72), SSI (OR: 1.67, 95%CI:1.11–2.51), unplanned 90-day readmissions (OR:
2.20; 95% CI:1.67–2.91) and a trend towards higher revision rate 1-year post-THA (HR: 1.32; 95% CI: 0.94–1.84),
than OA patients.
Conclusions: Compared to OA, a diagnosis of osteonecrosis was associated with worse outcomes post-THA.
A detailed preoperative discussion including the risk of complications is needed for informed consent from
patients with osteonecrosis.
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Diagnosis, Risk factor
* Correspondence: Jasvinder.md@gmail.com
“The views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs or the United States government.”
1Medicine Service, Birmingham VA Medical Center, Birmingham, AL, USA
2Department of Medicine at School of Medicine, and Division of
Epidemiology at School of Public Health, University of Alabama, Faculty
Office Tower 805B, 510 20th Street S, Birmingham, AL 35294, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Singh et al. BMC Musculoskeletal Disorders  (2017) 18:8 
DOI 10.1186/s12891-016-1385-0
Background
Total hip arthroplasty (THA) is a successful surgical
treatment for end stage arthritis [1]. The most common
underlying diagnosis in patients undergoing elective
THA is osteoarthritis (OA), followed by osteonecrosis,
congenital hip disorders, and inflammatory arthritis [2].
A systematic review of 67 studies with 2,593 patients
with 3,277 hips concluded that osteonecrosis was not
associated with higher revision rates after THA
compared to the other underlying diagnoses [3], with
minor exceptions. A small single-site retrospective study
of 31 patients with glucocorticoid-induced osteonecrosis
undergoing THA reported improvement in pain and
function with THA but high complication and reopera-
tion rates [4]; however, there were no controls.
Post-THA complications and associated hospital read-
missions are undesirable THA outcomes of great interest
clinically, due to associated morbidity. Post-arthroplasty
complications, such as surgical site infections (SSI) and
thromboembolic complications, are responsible for most
surgically related readmissions [5–7]. Overall, 90-day re-
admission rates range 7–8% after primary THA or pri-
mary total knee arthroplasty [7–9]. Readmission rate can
have a significant impact on health care resources, espe-
cially given the high volume of these procedures. Mor-
tality is rare after THA (mostly elective) and is
extremely undesirable.
We recently showed that an underlying diagnosis of
RA was associated with higher readmission rate com-
pared to OA [10]. To our knowledge, studies of compli-
cations and readmission rates in patients undergoing
THA with osteonecrosis are lacking. It is possible that
outcomes in patients with osteonecrosis undergoing
THA have improved over time due to the improvement
in bearing surfaces and ubiquitous use of cementless
fixation [11].
The objective of our study was to examine whether
compared to OA, an underlying diagnosis of osteonecro-
sis was associated with a higher adjusted risk of compli-
cations and readmissions after primary THA (study
hypothesis). We also performed exploratory analyses to
assess the association of the cause of osteonecrosis with
complications and readmissions post-primary THA.
Methods
We described study methods and results as recommended
in the Strengthening of Reporting in Observational studies
in Epidemiology (STROBE) statement [12].
Study design, data source, and patient sample
We performed a cohort study of patients who had
undergone an elective unilateral primary THA using
the Kaiser Permanente (KP) Total Joint Replacement
Registry (TJRR). We identified a cohort of patients
who underwent elective unilateral primary THA be-
tween 04/01/2001 and 12/31/2012. The KP is a inte-
grated healthcare system that covers over 9.5 million
members in 7 US geographical areas. We have previ-
ously reported details on the KP TJRR data collection
procedures, structure, and participation [13, 14]. The
KP TJRR uses paper and electronic data capture tools
to collect information by surgeons and other health-
care providers at the point of care, as well as data
from other databases (including the electronic medical
records) using electronic screening algorithms. The
information from different data sources of the registry
is linked using the integrated healthcare system’s
unique patient identifiers. The data repository for the
registry is a SQL database. A quarterly quality control
check of these data ensures high accuracy. Specific-
ally, the KP TJRR prospectively collects outcomes (i.e.
readmissions, revision, SSI, venous thromboembolism
(VTE)). Several outcomes including revision, SSI and
VTE are adjudicated by review of charts by trained
research associates [13, 14].
In a chart review of random sample of osteonecro-
sis and OA cases (n = 60; 30 cases each of osteo-
necrosis and OA) performed by an abstractor blinded
to the database diagnosis, we found that the true
positive rate of diagnoses (OA vs. osteonecrosis) was
88%. All registered cases in the KP TJRR are tracked
until outcome and/or end of their lives. The voluntary
participation of the KP TJRR in 2011 was 95% [14].
This study included all unilateral primary elective
THA procedures, in patients aged 18 years old or older,
with surgery indication for OA and/or osteonecrosis reg-
istered during the study period (N = 47,523). Patients
who had a diagnosis of both OA and osteonecrosis (N =
563) were not included in the study. Patients who under-
went revision THA, partial THA, or conversion proce-
dures, as the index procedure, were not included in the
study. This was done for two reasons: (1) the majority of
THA are elective primary THA, our condition of inter-
est; and (2) to keep the population homogeneous and
allow easy interpretation of results. Cases from the geo-
graphical regions where the organization owns the hos-
pitals (Southern California, Northern California, and
Hawaii), covering 92% of the KP TJRR registered cases,
were included. The final sample had cases from 50 hos-
pitals and 362 surgeons.
Outcome measures
The outcomes of interest in this study were mortality
within 90 days, SSI (30 days for superficial and 1 year
for deep infections), VTE within 90 days, unplanned
readmissions within 90 days of the index primary elect-
ive THA, and revision (ever and for any reason). All out-
come measures were obtained from the KP TJRR using
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2001–12 data; timing of outcome assessment was chosen
based on clinical relevance, based on feedback from an
expert surgeon (R.N.). SSIs, which can be either deep or
superficial were defined according to the Centers for
Disease Control and Prevention/National Healthcare
Safety Network criteria [15]. Superficial and deep SSI
were also combined into one measure in this study since
we anticipated a small number of events for these two
components individually. The VTE measure, which in-
cluded symptomatic deep vein thrombosis (DVT) and
pulmonary embolism (PE) in this study due to the small
number of events, were identified using the Agency for
Healthcare Research and Quality patient safety indica-
tors technical specifications [16] and further confirmed
by chart review validation by trained clinical research as-
sociates. Readmissions are captured by the KP TJRR
using quarterly extracts from the institutional electronic
medical records of all hospital readmissions post dis-
charge from the original joint arthroplasty procedure,
available from 2009. Only unplanned readmissions,
which were determined based on the 2014 Centers for
Medicare and Medicaid Services Procedure-Specific Re-
admission Measures Updates and Specification Report
for Elective Primary THA [17] were included in the ana-
lysis. Planned admissions such as those likely for subse-
quent hip arthroplasty procedures (e.g. International
Classifications of Disease, 9th Revision, code (ICD-9)
715.34, Osteoarthrosis, localized, pelvic region and thigh
and ICD-9: 733.42, aseptic necrosis of head and neck of
femur) were not included in the reported readmissions.
Revisions were defined as any re-operation of the index
procedure where a component was replaced.
Exposure of interest
An underlying diagnosis of osteonecrosis was the ex-
posure of interest, compared with a diagnosis of OA.
This information was obtained from the KP TJRR
intra-operative forms completed by the surgeon at the
time of surgery and does not rely on administrative
data coding schemes. We also explored the associa-
tions by the cause/type of osteonecrosis, categorized
as idiopathic vs. non-idiopathic, using the 2009–2012
data, the year of the beginning of prospective collec-
tion of intra-operative diagnosis and readmission data.
Additional file 1 shows the sub-categories of non-
idiopathic category glucocorticoid-induced vs. not
glucocorticoid-induced (including hip fracture, alcohol
abuse, sickle cell disease, lupus, pancreatitis, HIV, vas-
culitis and other autoimmune conditions).
Covariates and potential confounders
Age (<65 and ≥65 years old, based on Medicare-eligible
age of 65 years and higher), gender; race (White and
Others), body mass index (BMI, continuous in 5 unit
increment); American Society of Anesthesiologists
(ASA) class (<3 vs. ≥3), and medical comorbidities using
the Elixhauser co-morbidity measure [18] were evaluated
as possible confounders/covariates.
Statistical analyses
We calculated summary statistics to describe the study
sample by whether the primary diagnosis was osteo-
necrosis vs. OA. We compared categorical variables be-
tween the two groups using 2-sided chi-square or
Fisher’s exact tests where appropriate. A logistic regres-
sion was used to model the relationship between osteo-
necrosis (OA being the reference category) and
mortality, VTE, SSIs, and readmissions while accounting
for the nesting of observations within the surgeon vari-
able. We created Cox proportional hazard models to
evaluate the association of osteonecrosis compared to
OA and the time to revision surgery. Covariates tested
as confounders, were included in the final adjusted
model if they changed estimates by >10% and p < 0.10 or
deemed clinically important for the relationship studied.
Odds ratios (OR), hazard ratios (HR), 95% confidence
internals (CI), and p-values are reported. A sensitivity
analysis was conducted to evaluate the robustness of es-
timations accounting for missing data. We also per-
formed sensitivity analyses that adjusted for the
competing risk of death. No formal sample size calcula-
tions were done for this observational cohort study. Data
were analyzed using SAS (Version 9.2, SAS Institute,
Cary, NC, USA) and p-value <0.05 was considered statis-
tical significant.
Results
Demographic and clinical characteristics of study sample
There were 47,523 patients included in the study from
2001 to 12. Of these, 2,271 (4.8%) had an underlying
diagnosis of osteonecrosis. Demographic and clinical fea-
tures of patients with osteonecrosis are shown in Table 1.
Compared to the cohort of patients with OA, the osteo-
necrosis group was younger (median (interquartile range
(IQR)): 55 (46–64) vs. 67 (59–75)) years old, had more
males (1,306 (57.5%) vs. 18,875 (41.7%)), and had less
White (1,358 (59.8%) vs. 35,009 (77.4%)) patients. Pa-
tients with osteonecrosis had lower BMI (<30 kg/m2:
1,505 (66.3%) vs. 26,358 (58.3%)), slightly higher ASA
scores (ASA ≥ 3: 897 (39.5%) vs. 15,827 (35.0%)), and
were less likely to have diabetes (451 (19.9%) vs. 10,042
(22.2%)). Additional file 2 shows that several comorbidi-
ties were more prevalent in patients with osteonecrosis
compared with those with osteoarthritis.
Between 2009 and 2012 (period of prospective collec-
tion of intra-operative diagnosis and readmission data),
of a total of 670 patients, 507 (76%) had idiopathic
osteonecrosis and 163 (24%) had non-idiopathic
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osteonecrosis. Among the non-idiopathic category, 40
(6%) patients had glucocorticoid-induced osteonecrosis
and 123 (18%) patients had causes other than
glucocorticoid-induced osteonecrosis. Additional file 3
shows that patient characteristics were similar between
idiopathic vs. non-idiopathic etiology; similarly Add-
itional file 4 shows that characteristics were similar be-
tween glucocorticoid-induced vs. not glucocorticoid-
induced osteonecrosis.
Crude outcome incidence
Compared to patients with OA, patients with osteonecro-
sis had higher incidence of the following complications
post-THA: 90-day mortality (0.7% vs. 0.3%), SSI (com-
bined: 1.2% vs. 0.8%; 90-day deep infection: 0.6% vs. 0.5%;
30-day superficial infection: 0.6% vs. 0.3%), 90-day VTE
(1.4% vs. 1.2%, DVT: 0.8% vs. 0.7%, PE: 0.6% vs. 0.5%), 90-
day unplanned readmission (9.6% vs. 5.2%) and revision at
any time during the follow-up (3.1% vs. 2.4%; Table 2).
The median follow up time for revision outcome was
3.2 years (Interquartile range, 1.4–5.8). Unadjusted
revision-free survival showed a trend favoring osteoarth-
ritis compared to osteonecrosis (Fig. 1; p = 0.108).
Additional files 5 and 6 shows that the unadjusted rates
of outcomes were similar by underlying cause of osteo-
necrosis except the following: higher 90-day readmission
Table 1 Study cohort characteristics by primary diagnosis at total hip arthroplasty surgery
Total Osteoarthritis Osteonecrosis
n % n % n %
Total N 47,523 100.0 45,252 95.2 2,271 4.8
Age, years Median (IQR) 66.0 (58.0–74.0) 67.0 (59.0–75.0) 55.0 (46.0–64.0)
Age category, years <65 20,899 44.0 19,195 42.4 1,704 75.0
≥65 26,624 56.0 26,057 57.6 567 25.0
Gender Male 20,181 42.5 18,875 41.7 1,306 57.5
Female 27,341 57.5 26,376 58.3 965 42.5
Race White 36,367 76.5 35,009 77.4 1,358 59.8
Black 3,637 7.7 3,324 7.4 313 13.8
Hispanic 3,283 6.9 3,030 6.7 253 11.1
Asian 1,606 3.4 1,436 3.2 170 7.5
Other/Multi-racial 753 1.6 707 1.6 46 2.0
Unknown 1,877 4.0 1,746 3.9 131 5.8
BMI categorya, kg/m2 <30 27,863 58.6 26,358 58.3 1,505 66.3
≥30 and <35 11,625 24.5 11,170 24.7 455 20.0
≥35 7,394 15.6 7,138 15.8 256 11.3
ASA categorya 1 and 2 29,312 61.7 28,008 61.9 1,304 57.4
≥3 16,724 35.2 15,827 35.0 897 39.5
Diabetes 10,493 22.1 10,042 22.2 451 19.9
IQR interquartile range, BMI body mass index, ASA American Society of Anesthesiologists
aMissing data: BMI (1.4%), ASA (3.1%)
Table 2 Crude incidence of outcomes by primary diagnosis at
total hip arthroplasty surgery
Osteoarthritis Osteonecrosis
n % n %
Death, 90 days 138 0.3 15 0.7
Surgical site infection, any 367 0.8 27 1.2
Deep, 1-yeara 230 0.5 13 0.6
Superficial, 30-daysb 137 0.3 14 0.6
Venous thromboembolism, 90-days 551 1.2 31 1.4
Deep vein thrombosisc 323 0.7 18 0.8
Pulmonary embolismd 228 0.5 13 0.6
Readmission, 90 days unplannede 846 5.2 64 9.6
Revision, everf 1,075 2.4 70 3.1
aDeep surgical site infection excluded patient who died or left the system
within 1 year without deep SSI (1549, 3.3%), n = 45974 (96.7%)
bSuperficial surgical site infection excluded patient who died or left the system
within 30 days without superficial SSI (138, 0.3%), n = 47385 (99.7%)
cDeep vein thrombosis (DVT) excluded patient who died or left the system
within 90 days without DVT (376, 0.8%), n = 47147 (99.2%)
dPulmonary embolism (PE) excluded patient who died or left the system
within 90 days without PE (374, 0.8%), n = 47149 (99.2%)
eReadmissions includes limited sample (operative years 2009–2012 and 3
geographical regions), n = 17179. Excluded patient who died or left the system
within 90 days without readmission (85, 0.5%), final n = 17094 (99.5%)
fThe median follow-up for revision outcome was 3.2 years (inter-quartile
range, 1.4–5.8 years)
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(14.7% vs. 7.7%) and revision rates (3.1% vs. 1.2%) in non-
idiopathic group vs. idiopathic group (see Additional file 5);
and higher 90-day readmission rate (17.5% vs. 13.8%)
in glucocorticoid-induced vs. not glucocorticoid-induced
osteonecrosis (see Additional file 6),
Adjusted odds of mortality, SSI, VTE and readmission and
adjusted risk of revision
After adjusting for age, race, BMI, and ASA class, the
risk of 90-day mortality was significantly higher for pa-
tients with osteonecrosis than OA for the overall sample
Fig. 1 Revision Free Survival Estimates for Cohorts with Osteonecrosis and Osteoarthritis. The figure shows the hip implant survival curve
comparing osteoarthritis to osteonecrosis after primary total hip arthroplasty. The unadjusted revision-free survival showed a trend favoring
osteoarthritis compared to osteonecrosis (p = 0.108)
Table 3 Unadjusted and adjusted association of osteonecrosis with death, surgical site infection (SSI), venous thromboembolism
(VTE), and revision compared to osteoarthritis in patients undergoing total hip arthroplasty
Osteonecrosis vs. Osteoarthritis Unadjusted OR (95%CI) p-value Adjusted OR (95%CI) p-value
Death, 90 daysa 2.12 (1.23–3.66) 0.007 2.48 (1.31–4.72) 0.006
SSI (deep and superficial)b 1.45 (0.97–2.18) 0.069 1.67 (1.11–2.51) 0.013
VTE (DVT and PE), <90 daysc 1.16 (0.78–1.70) 0.466 1.37 (0.92–2.03) 0.118
Readmission, 90 days unplannedd 1.89 (1.43–2.48) <0.001 2.20 (1.67–2.91) <0.001
Unadjusted HR (95%CI) p-value Adjusted HR (95%CI) p-value
Revision (within 1 Year)e 1.00 (0.70–1.44) 0.992 0.92 (0.63–1.33) 0.652
Revision (after 1 Year) 1.44 (1.04–2.01) 0.030 1.32 (0.94–1.84) 0.109
SSI surgical site infection, as defined by the CDC, VTE venous thromboembolism, DVT deep vein thrombosis, PE pulmonary embolism- as defined by AHRQ, OR
odds ratio, HR hazard ratio, CI confidence interval
All multivariable models were adjusted for covariates if they changed estimates by >10% and p < 0.10 in univariate analyses or deemed clinically important for the
relationship studied
aAdjusted model excluded cases with missing BMI (641, 1.4%) and ASA (1,487, 3.1%), final n = 45,431 (95.6%). Multivariable-adjusted model was adjusted for age,
race, BMI, and ASA
bThe combined SSI includes 30-day superficial SSI and 1-year deep SSI. Adjusted model excluded cases with missing BMI (641, 1.4%), ad patients who died or left
the system within 1 year (1,539, 3.2%), final n = 45506 (95.8%). Multivariable-adjusted model was adjusted for BMI
cThe combined VTE outcome includes deep vein thrombosis and pulmonary embolism. Adjusted model excluded cases where patients either died or left the
system within 90 days (n = 370, 0.8%), final n = 47,153 (99.2%). Multivariable-adjusted model was adjusted for age
dReadmissions includes limited sample (operative years 2009–2012 and 3 geographical regions), n = 17,179. Final adjusted model excluded cases where patients
either died or left the system within 90 days (n = 85, 0.5%), final n = 17,094 (99.5%). Multivariable-adjusted model was adjusted for age
eAdjusted model had no exclusions due to missing values, n = 47,523 (100%). Multivariable-adjusted model was adjusted for age
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(OR: 2.48; 95% CI, 1.31–4.72) (Table 3). After adjusting
for BMI, the odds of SSI (deep and superficial) in pa-
tients with osteonecrosis were 1.67 (95% CI: 1.11–2.51)
times higher than patients with OA (Table 3). In the
age-adjusted model, the risk of VTE (DVT and PE) was
not statistically significantly different between two
groups (OR: 1.37; 95% CI, 0.92–2.03) (Table 3). After
adjusting for age, 90-day unplanned readmission was
statistically significantly higher in patients with osteo-
necrosis than those with OA (OR: 2.20; 95% CI,
1.67–2.91) (Table 3).
A time interaction was observed for revision after
adjusting for age. While the risk estimates for revision
surgery were not statistically significant overall, the dir-
ection of the risk estimates changed for patients within
one year of the surgery vs. longer time, for OA vs. osteo-
necrosis. Specifically, compared to patients with OA, pa-
tients with osteonecrosis did not have any significantly
different hazard of revision (HR = 0.92, 95% CI: 0.63–
1.33) within one year of the surgery, but after one year,
patients with osteonecrosis seemed to have a 1.32-times
higher (95% CI: 0.94–1.84) hazard of revision surgery
(Table 3).
Exploring differences by the underlying cause of osteo-
necrosis, the age-adjusted 90-day readmission was sig-
nificantly higher in non-idiopathic vs. idiopathic group,
with adjusted odds ratio of 2.13 (95% CI: 1.23–3.68).
Additional file 7 shows that the revision rate seemed
higher, but did not meet statistical significance.
Additional file 8 shows that there was no significant differ-
ence in 90-day readmission was noted in glucocorticoid-
induced vs. not glucocorticoid-induced osteonecrosis.
Reasons for readmission
The five most common principal discharge ICD-9 codes
for the unplanned 90-day readmissions in patients with
osteonecrosis were as follows: 996.42 (Dislocation of
prosthetic joint), 038.9 (Unspecified septicemia), 486
(Pneumonia), 282.62 (Hemoglobin SS disease, sickle cell
disease with crisis), and 493.22 (Chronic obstructive lung
disease/asthma with exacerbation). In comparison, the
five most common principal discharge ICD 9 codes for
90-day readmissions in patients with OA were as fol-
lows: 996.42 (dislocation of prosthetic joint), 996.66 (in-
fection & inflammation reaction due to internal joint
prosthesis), 998.59 (other postoperative infection), 38.9
(unspecified septicemia), and 996.44 (periprosthetic frac-
ture around prosthetic joint). Additional file 9 shows the
top 15 causes for readmission.
Sensitivity analyses: missing data and competing risk of
death
The impact of the 2,092 (4.4%) missing data
(1,487 (3.1%) in ASA class, 1 (0.0%) in gender, and 641
(1.3%) in BMI) was evaluated. The distribution of other
patient characteristics between patients with missing
data and those with complete data were not different.
The crude incidence rates for all outcomes were not sta-
tistically significantly different except for 90-day mortal-
ity (1.2% in patients with missing data vs. 0.3% others).
To evaluate the impact of these missing data points in
the estimations, we modeled diagnoses and 90-day mor-
tality without BMI and ASA adjustments and found 90-
day mortality for patients with osteonecrosis was in-
creased (OR: 3.39; 95% CI, 1.93–5.96, p < 0.001), indicat-
ing that main analyses provided conservative estimates.
Sensitivity analyses that adjusted for competing risk of
death showed that there were no changes in any of the
above analyses (data available on request).
Discussion
In this study of 47,523 patients in KP TJRR registry
undergoing primary THA, of whom 2,271 had osteo-
necrosis, we found that an underlying diagnosis of osteo-
necrosis was associated with higher risk of SSI, 90-day
readmission and mortality following THA compared to
OA. To our knowledge, our study is one of the most
comprehensive studies to quantify the rate of several
complications and unplanned 90-day readmission post-
THA in a large, representative total joint registry study
with validated outcomes. Our study overcomes a key
limitation of previous studies, i.e., lack of a comparator
group [3]. Our study also fills an important knowledge
gap, i.e., are clinically important outcomes including re-
vision surgery higher in patients with osteonecrosis?
Several findings are novel and deserve further
discussion.
The 90-day readmission rates following THA were
50% higher in patients with osteonecrosis compared
to OA. To our knowledge, this is a novel finding of
high interest to surgeons and policyholders. In ab-
sence of any previously published studies, this is the
first study to demonstrate this difference. Readmission
after an elective surgery such as THA can signifi-
cantly influence health care utilization. Given that
osteonecrosis is the second most common reason for
primary THA, this excess utilization is clinically
meaningful. With 332,000 THAs performed in 2010
in the US, the 90-day post-THA unplanned readmis-
sion rate of 6.8% translates into >12,000 admissions
annually. Our finding of higher unplanned readmis-
sion rates in patients with osteonecrosis post-THA
with an odds ratio of 2.20 adds to our recent study
finding that RA was associated with 74% higher 90-
day readmission compared to OA in patients under-
going THA or total knee arthroplasty [19].
We hypothesized the following potential reasons for
a higher rate of readmission in patients with
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osteonecrosis compared to OA: (1) a higher rate of
corticosteroid use or alcohol consumption, frequent
causes of osteonecrosis (as noted by us, Additional
file 1); (2) higher comorbidity and complexity in pa-
tients with osteonecrosis (higher ASA class in a previ-
ous study) [20]; (3) association of osteonecrosis with
conditions such as trauma, autoimmune diseases and
coagulation abnormalities, which are potential risk
factors for poor THA outcomes; and (4) potential dif-
ferences in bone structure and quality in osteonecro-
sis vs. OA, which might be related to implant-related
complications. In fact, our data show that the preva-
lence of certain comorbidities (e.g. liver disease,
chronic liver disease, deficiency anemia, alcohol
abuse) was higher in patients with osteonecrosis.
The 90-day mortality was 2.5-times higher in pa-
tients with osteonecrosis who underwent primary
THA, compared to OA. Due to the limitation of most
previous studies of osteonecrosis to patients under
the age of 50 years (and even smaller sample sizes),
the ability to study a rare outcome, such as mortality,
was previously limited. A large study sample size
allowed us to assess this outcome appropriately. As
noted above, a higher rate of comorbidity and poten-
tially corticosteroid-associated complications in pa-
tients with osteonecrosis, may have contributed to
higher mortality rates. Regardless of the cause, pa-
tients with osteonecrosis undergoing primary THA
should be made aware of our finding of a significant
difference in mortality post-THA compared to OA
patients undergoing THA, providing them with rela-
tive and absolute risk. Based on our study findings,
more studies into the etiology of this rare, but critical
outcome are needed in patients with osteonecrosis. A
better understanding of modifiable risk factors that
are associated with excess mortality can allow them
to be targeted for interventions aimed at reducing
mortality in patients with osteonecrosis undergoing
primary THA.
Another important and new clinical finding from
our study was the higher risk of SSI in patients with
osteonecrosis undergoing primary THA. Corticoster-
oid use, alcohol use or autoimmune diseases, risk
factors for osteonecrosis, may also increase the risk
of SSIs, due to known associations of these factors
with the risk of infections [21–23]. One study of pa-
tients with glucocorticoid-induced osteonecrosis in
patients undergoing THA without any controls
showed a high complication rate [4]. Our study adds
to this literature by showing that outcomes such as
SSIs occurred more frequently in the overall cohort
of patients with osteonecrosis undergoing primary
THA, not just those with glucocorticoid-induced
osteonecrosis.
In exploratory analyses by the underlying cause of
osteonecrosis, adjusted 90-day readmission was sig-
nificantly higher (2.13-times) and revision rate border-
line higher, in non-idiopathic vs. idiopathic group.
This is not surprising considering that comorbidities
(alcohol abuse, lupus, hip fracture etc.) in the non-
idiopathic are potential risk factors for poor outcomes
and readmissions. Numbers for complications/out-
comes by glucocorticoid-induced vs. other causes of
osteonecrosis were too small to allow any meaningful
comparison.
Our study has several limitations. Despite our ef-
forts to control for several covariates and confounders
in our observational study, residual confounding bias
is possible. We were unable to investigate the out-
comes of osteonecrosis by each underlying reason
(corticosteroid, alcohol abuse, sickle cell disease, lupus
etc.), due to the limitation of the number of patients
with these diagnoses in our cohort, making the ana-
lyses very underpowered to perform any analyses. Lar-
ger studies in the future (perhaps data from national
arthroplasty registries or data from several national
registries combined) should investigate whether osteo-
necrosis associated with sickle cell, alcohol abuse etc.
has worse outcome than other causes of osteonecro-
sis. These findings may not be generalizable to the
U.S. general population; however, the membership of
KP has been shown to be demographically and socio-
economically representative of the geographical re-
gions it covers [24, 25]. The study strengths include a
large sample size, comparison of OA to osteonecrosis
and the adjustment for important covariates. Some
patients may have died before having one of the out-
come measures because we treated each outcome as
an independent event. Therefore, it is possible that
we underestimated the incidence of the other compli-
cations. However, we performed models with death as
the competing risk that showed no change in ana-
lyses, indicating that the associations of osteonecrosis
we noted were not affected by the competing mortal-
ity risk.
Conclusions
In summary, we found patients with osteonecrosis
had higher risk of mortality, SSI and unplanned re-
admission post-THA, compared to patients with OA.
These differences were both clinically meaningful
and statistically significant. Our study findings have
clinical implications. Surgeons can discuss increased
rates of these complications/risks (absolute and rela-
tive) with patients with osteonecrosis before obtain-
ing informed consent from patients undergoing
THA. Our study also has implications for future
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research. We identified several aspects of poorer
outcomes in patients with osteonecrosis compared to
those with OA that need further investigation. Re-
search into the underlying reasons for higher com-
plication rate in patients with osteonecrosis
undergoing primary THA should help understand
this key clinical problem.
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